Sector News

Kimberly Blackwell, M.D., to join Lilly Oncology in VP role

December 12, 2017
Life sciences

Eli Lilly and Company today announced that Kimberly Blackwell, M.D., one of the nation’s leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018.

Dr. Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as the co-director of the Duke women’s cancer program, associate director for strategic relations for the Duke Cancer Institute, research scholar for Susan G. Komen, and senior strategist for the Duke Innovation and Entrepreneurship Program. She will report to Levi Garraway, M.D., Ph.D., senior vice president, Global Development & Medical Affairs of Lilly Oncology.

“We are pleased and honored to welcome Dr. Blackwell to Lilly,” said Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology. “She is highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programs that resulted in numerous groundbreaking regulatory approvals in the oncology sector.”

“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”

Source: Eli Lilly and Company

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).